Silexion Therapeutics Ltd.
SLXNW · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $0 |
| - Cash | $9 | $3 | $6 | $1 |
| + Debt | $0 | $4 | $3 | $4 |
| Enterprise Value | -$9 | $0 | -$2 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$2 | -$2 | -$6 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$3 | -$2 | -$2 |
| % Margin | – | – | – | – |
| EPS Diluted | 2.88 | -4.32 | 0.26 | -2.7 |
| % Growth | 166.7% | -1,761.5% | 109.6% | – |
| Operating Cash Flow | -$3 | -$3 | -$2 | -$3 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$3 | -$3 | -$2 | -$3 |